Concepedia

Lee Smolen

LS

Statistics

Publications

9

Citations

262

H-Index

9

Active since

2007

Affiliations

Medical Decision Modeling (United States)(Current)

Eli Lilly (United States)

Emory University

Texas A&M Health Science Center

Lee Smolen is an author at Medical Decision Modeling (United States) specializing in pharmacoeconomics, cost-effectiveness modeling, and pharmacy.

ORCID

Publications per year

2007–2023

9

Publications

9

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Daniel R. Murphy, Lee Smolen, Timothy Klein et al. · BMC Musculoskeletal Disorders · 2012 · 49 citations · Full text

, , +17

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Nicolas M. Furiak, Haya Ascher‐Svanum, Robert W. Klein et al. · Cost Effectiveness and Resource Allocation · 2009 · 44 citations · Full text

, , +17

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States

Haya Ascher‐Svanum, Nicolas M. Furiak, Anthony H. Lawson et al. · Journal of Medical Economics · 2012 · 36 citations

, , +17

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma

Sundar Jagannath, N.R. Joseph, Concetta Crivera et al. · Oncology and Therapy · 2023 · 31 citations · Full text

, , +17

Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia

Eric S. Meadows, Robert W. Klein, Matthew D. Rousculp et al. · BMC Women s Health · 2007 · 30 citations · Full text

, , +16

1–5 of 9